LLY · 10-Q · 2026Q1 · Full report

Incretin product concentration

ELI LILLY & Co · 2026-04-30 · Importance 71 · Surprise 60

Mounjaro and Zepbound together accounted for 65% of Lilly's total revenue for the three months ended March 31, 2026, making cardiometabolic/incretin products the dominant revenue driver. The company notes FDA approval of Foundayo (orforglipron) for obesity and that Mounjaro has been launched in all major markets, supporting further volume growth. Lilly highlights that anticipated demand across new incretin channels and markets (including U.S. Medicare) will materially affect near-term performance and that manufacturing expansions are underway to support expected demand. The company states that long‑term durability of cardiometabolic offerings depends on maintaining competitive positioning and delivering additional innovation to sustain growth momentum.

Key facts

• Mounjaro and Zepbound accounted for 65 percent of our total revenue for the three months ended March 31, 2026. source